Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is inviting applications for the "Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed)" funding opportunity, aimed at advancing interdisciplinary research in developing complex 3D in vitro microphysiological systems (MPS) that model aging processes observed in vivo. The initiative primarily focuses on human cell-derived MPS, encouraging innovative approaches from various fields such as aging biology, stem cell biology, and bioengineering, with the goal of enhancing the adoption of MPS in aging biology research and drug discovery. NIH plans to allocate $2.4 million in FY 2026 for approximately 10 awards, with each project budget capped at $275,000 in direct costs over two years. Interested applicants can find more details and submit inquiries via grantsinfo@nih.gov, with applications due by October 20, 2025.
Eligible Applicants
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.